aldosterone has been researched along with imatinib mesylate in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akashi, K; Haji, S; Hirata, A; Kato, K; Kimura, D; Masuda, T; Miyamoto, T; Nakashima, N; Nakashima, Y; Nojiri, C; Ogawa, Y; Shiratsuchi, M; Tokunaga, S; Tsuda, M | 1 |
1 other study(ies) available for aldosterone and imatinib mesylate
| Article | Year |
|---|---|
Rapid decrease in eGFR with concomitant use of tyrosine kinase inhibitors and renin-aldosterone-angiotensin system inhibitors in patients with chronic myelogenous leukemia.
Topics: Aldosterone; Angiotensins; Antihypertensive Agents; Enzyme Inhibitors; Glomerular Filtration Rate; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Renin; Retrospective Studies | 2022 |